Jacalyn Rosenblatt, MD
Beth Israel Deaconess Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jacalyn Rosenblatt, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:25 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07377435 · DC/MM Fusion Vaccine With BCMA CAR-T in R/R MMDavid Avigan · recruiting · Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma · principal investigator
- Ph1/Ph2NCT04477642 · Abatacept for Patients With COVID-19 and Respiratory DistressBeth Israel Deaconess Medical Center · withdrawn · COVID-19 · principal investigator
- Ph2NCT03782064 · Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple MyelomaBeth Israel Deaconess Medical Center · terminated · Multiple Myeloma · principal investigator
- Ph1NCT03679650 · Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML PatientsBeth Israel Deaconess Medical Center · active not recruiting · Acute Myelogenous Leukemia · principal investigator
- Ph2NCT03059485 · DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced RemissionBeth Israel Deaconess Medical Center · active not recruiting · Acute Myelogenous Leukemia · principal investigator
- Ph1NCT02658396 · GO-203-2C + Bortezomib For Relapsed Or Refractory MMDana-Farber Cancer Institute · withdrawn · Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma · principal investigator
- Ph1/Ph2NCT01954979 · Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)Beth Israel Deaconess Medical Center · completed · Chronic Graft Versus Host Disease · principal investigator
- N/ANCT01472627 · Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in VitroDana-Farber Cancer Institute · completed · Multiple Myeloma · principal investigator
- Ph2NCT01096602 · Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced RemissionBeth Israel Deaconess Medical Center · completed · Acute Myelogenous Leukemia, AML · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:25 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Targeting SYK Kinase in AMLP50CA206963 · NCI · DANA-FARBER CANCER INST · PI Kimberly Stegmaier · fiscal years 2017 to 2021Named on NCT03679650
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.